| Characteristics | Total (N = 43) | KDIGO 1 (n = 9) | KDIGO 2 (n = 9) | KDIGO 3 (n = 25) | p-value |
| Age |
|
|
|
| 0.9116 |
| <60 years | 79% (34/43) | 55.6% (5/9) | 66.7% (6/9) | 52% (13/25) |
|
| ≥60 years | 21% (9/43) | 44.4% (4/9) | 33.3% (3/9) | 48% (12/25) |
|
| Gender |
|
|
|
| 0.01403 |
| Male | 79% (34/43) | 100% (9//9) | 44.4% (4/9) | 84% (21/25) |
|
| Female | 21% (9/43) | 0 | 55.6% (5/9) | 16% (4/25) |
|
| Comorbidities |
|
|
|
|
|
| Hypertension | 58% (25/43) | 77.8% (7/9) | 44.4% (4/9) | 56% (14/25) | 0.4014 |
| Diabetes | 34.9% (15/43) | 44.4% (4/9) | 55.6% (5/9) | 24% (6/25) |
|
| Heart diseases | 14% (6/43) | 33.3% (3/9) | 0 | 12 (3/25) | 0.143 |
| Clinical signs |
|
|
|
|
|
| Hypotension | 2.3% (1/43) | 0 | 11,1% (1/9) | 0 | 0.4186 |
| Fever | 16.3% (7/43) | 22.2% (2/9) | 0 | 20% (5/25) | 0.5102 |
| Respiratory distress | 60.5% (26/43) | 66.7% (6/9) | 33.3% (3/9) | 68% (17/25) | 0.7039 |
| Biological signs |
|
|
|
|
|
| Hemoglobin < 12 g/dl | 37.2% (16/43) | 55.6% (5/9) | 33.3% (3/9) | 32% (8/25) | 0.4717 |
| Hyperkalemia | 27.9% (12/43) | 11.1% (1/9) | 22.2% (2/9) | 36% (9/25) | 0.3357 |
| Uremia (g/l) |
|
|
|
| 0.1875 |
| <2 | 51.2% (22/43) | 22.2% (2/9) | 55.6% (5/9) | 60% (15/25) |
|
| ≥2 | 48.8% (21/43) | 77.8% (7/9) | 44.4% (4/9) | 40% (10/25) |
|
| CT lesions |
|
|
|
|
|
| Interstitial | 51.2% (22/43) | 44.4% (4/9) | 44.4% (4/9) | 56% (14/25) |
|
| Alveolar | 18.6% (8/43) | 0 | 22.2% (2/9) | 24% (6/25) | 0.5941 |
| Pleurisy | 46.5% (20/43) | 44.4% (4/9) | 33.3% (3/9) | 52% (13/25) | 0.7667 |
| Type of kidney involvement |
|
|
|
| 0.00124 |
| ATN | 44.2% (19/43) | 0 | 22.2% (2/9) | 68% (17/25) |
|
| FKI | 32.6% (14/43) | 55.6% (5/9) | 44.4% (4/9) | 20% (5/25) |
|
| Not determined | 23.3% (10/43) | 44.4% (4/9) | 33.3% (3/9) | 12% (3/25) |
|
| Duration of the disease |
|
|
|
| 0.4306 |
| <7 days | 14% (6/43) | 22.2% (2/9) | 0 | 16% (4/25) |
|
| ≥7 days | 86% (37/43) | 77.8% (7/9) | 100% (9/9) | 84% (21/25) |
|
| Treatment |
|
|
|
|
|
| Antibiotics | 93% (40/43) | 100% (9/9) | 100% (9/9) | 88% (22/25) | 0.5624 |
| Anticoagulants | 65.1% (28/43) | 55.6% (5/9) | 44.4% (4/9) | 76% (19/25) | 0.1872 |
| Corticosteroids | 65.1% (28/43) | 44.4% (4/9) | 77.8% (7/9) | 68% (17/25) |
|
| Vasoactive amines | 34.9% (15/43) | 55.6% (5/9) | 11.1% (1/9) | 36% (9/25) | 0.1501 |
| Invasive ventilation | 44.2% (19/43) | 33.3% (3/9) | 33.3% (3/9) | 52% (13/25) | 0.3454 |
| Hemodialysis | 48.8% (21/43) | 11.1% (1/9) | 33.3% (3/9) | 68% (17/25) | 0.00685 |
| Evolution |
|
|
|
| 0.02758 |
| Death | 55.8% (24/43) | 77.8% (7/9) | 22.2% (2/9) | 60% (15/25) |
|
| Chronic | 16.3% (7/43) | 22.2% (2/9) | 33.3% (3/9) | 8% (2/25) |
|
| Recovery | 27.9% (12/43) | 0 | 44.4 (%4/9) | 32% (8/25) |
|